Chardan Capital Reaffirms “Buy” Rating for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reiterated by stock analysts at Chardan Capital in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $212.00 price objective on the stock. Chardan Capital’s price target suggests a potential upside of 31.82% from the company’s previous close.

Several other research analysts also recently commented on KRYS. HC Wainwright reaffirmed a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a report on Wednesday. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Citigroup raised their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Finally, Stifel Nicolaus lifted their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $206.67.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $160.83 on Wednesday. Krystal Biotech has a fifty-two week low of $107.50 and a fifty-two week high of $219.34. The company has a market cap of $4.63 billion, a PE ratio of 90.86 and a beta of 0.80. The stock’s fifty day moving average price is $180.46 and its two-hundred day moving average price is $185.00.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the prior year, the firm earned ($0.67) EPS. The firm’s revenue was up 879.9% compared to the same quarter last year. On average, equities analysts predict that Krystal Biotech will post 2.97 EPS for the current fiscal year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now directly owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KRYS. Franklin Resources Inc. raised its stake in Krystal Biotech by 34.2% in the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after acquiring an additional 62,178 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Krystal Biotech in the third quarter worth about $40,000. Teachers Retirement System of The State of Kentucky increased its stake in shares of Krystal Biotech by 198.2% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 9,010 shares of the company’s stock worth $1,640,000 after purchasing an additional 5,989 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Krystal Biotech by 2.0% in the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after purchasing an additional 11,411 shares during the period. Finally, Main Management ETF Advisors LLC purchased a new stake in shares of Krystal Biotech during the 3rd quarter valued at approximately $706,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).